How long do fillers last? A full breakdown by area

“How long do fillers last?” sounds like a question that should have a simple answer. In reality, there are at least three different things people may mean: how long the cosmetic effect remains noticeable, how long the injected hyaluronic acid remains physically present, and when a patient may reasonably want the area reassessed.

Those timelines are not always the same. A lip can look less full while some filler is still present. Mid-face filler can remain detectable on imaging long after the visible contour has softened. A patient may also feel ready for a review before the product has disappeared — or may need no additional treatment even when the original result has changed.

The area treated matters, but it is only one variable. Product formulation, injected volume, tissue plane, facial movement, previous filler, individual biology and the way “longevity” is measured can all change the answer.

Most modern facial fillers used for temporary soft-tissue augmentation are based on cross-linked hyaluronic acid (HA). The word “temporary” is correct, but it does not mean every HA product disappears on the same schedule.

Clinical trials use different outcome measures. Some assess whether a wrinkle or hollow is still improved. Others measure three-dimensional volume, ultrasound thickness or MRI signal. A patient can therefore fall below a clinical “responder” threshold while measurable filler is still present.

This is why a single statement such as “all filler lasts 6–12 months” is too crude. It may be a useful consumer shorthand for some indications, but it does not describe the full biological picture.

Recent imaging research has changed the filler-longevity conversation. A 2024 MRI review of 33 mid-face patients found residual cross-linked HA in every patient scanned more than two years after injection, with some patients showing detectable material many years later. That was a small observational cohort and should not be generalised to every product or facial area, but it demonstrates that visible correction and complete disappearance are not the same event.

A 2026 systematic review of clinical durability also found substantial persistence at 12 and 24 months across multiple HA technologies, while ultrasound studies in the review showed product persistence beyond a year in some settings.

The practical implication is simple: retreatment should not be based only on the date of the previous injection. The area should be reassessed.

Lip filler is often described as one of the shorter-lasting facial applications because the lips move constantly and the products used there are generally selected for flexibility rather than maximum structural stiffness.

Randomised and prospective trials have shown clinically meaningful lip correction through six to twelve months for several HA formulations. Some modern studies report measurable or patient-rated benefit beyond one year, but the proportion of patients maintaining the original level of fullness falls over time.

A range such as “6–12 months” is therefore a reasonable broad expectation for many lip treatments, but it should not be treated as an expiry date. Some patients notice the result softening earlier; others retain visible or palpable product longer.

The need for repeat treatment should be based on the settled appearance and the patient’s goal, not simply on reaching month six.

The cheeks and mid-face are different from the lips. Filler is often placed more deeply for structural support, and the tissues are generally less mobile than the mouth.

Prospective studies of volumising HA fillers have documented improvement through 12 to 18 months. More importantly, MRI research now shows that residual HA can remain in the mid-face far longer than traditional consumer timelines suggest.

That does not mean the cosmetic result remains unchanged for years. Volume redistribution, tissue ageing and partial degradation can alter the visible effect even when filler is still detectable.

This distinction matters when considering additional cheek filler. Adding more product because “it has been a year” can lead to cumulative volume if previous material is still present.

The tear trough is a low-movement area where relatively small volumes are used. Older studies demonstrated correction for around one year, and three-dimensional imaging has shown residual effect beyond twelve months in some patients.

A recent retrospective study specifically examined long-term tear-trough filler and challenged the assumption that all under-eye HA has disappeared by six to twelve months.

This is clinically relevant because persistent or repeated under-eye filler can contribute to fullness, contour irregularity or oedema in susceptible patients. The answer to “Is it time for more?” is therefore especially anatomy-dependent in this region.

Dark circles should also not be used as a proxy for filler disappearance. Pigmentation, visible vessels, skin quality, fat prolapse and oedema can all affect the under-eye appearance even when volume correction remains.

Chin and jawline fillers are usually selected for structural support and are often placed in deeper tissue planes. Modern prospective studies show meaningful improvement through twelve months, and some volumising HA products have maintained clinical effect for longer follow-up periods.

These areas are not motionless, but they generally experience less repetitive deformation than the lips. Product elasticity, cohesivity, injected volume and whether treatment is supraperiosteal or soft-tissue based all influence the result.

A common mistake is to assume that a denser filler automatically lasts a fixed 18 months. Product-specific trial data are more useful than generic claims, and individual response still varies.

The temples are relatively low movement, and clinical studies of HA volumisation have reported sustained improvement through at least twelve months. More recent randomised data also show maintained treatment response through approximately one year.

The temporal region is anatomically complex, however, and longevity should never be the only consideration. Vascular anatomy, tissue depth, previous filler and the amount of hollowing affect both suitability and safety.

Because the area can hold filler longer than patients expect, reassessment before repeat treatment is important.

Nose filler is another area where simple longevity ranges can be misleading. A dedicated literature review found that many studies reported around eight to twelve months of effect, while others reported substantially longer persistence.

A 2024 retrospective study of a standardised HA technique reported a median treatment effect of approximately eleven months, and randomised clinical data have demonstrated maintained change at twelve months for selected nasal indications.

The nose also has a distinct safety profile. It contains a dense vascular network with connections to the ophthalmic circulation, so rare complications can include skin necrosis and visual loss. A longer duration should never be framed as the main reason to choose nasal filler.

Repeat treatment should be conservative and assessment-led, particularly after previous rhinoplasty or prior filler.

Nasolabial folds, marionette lines and perioral lines are often grouped together online, but different products and depths may be used in each area.

Prospective trials have shown HA correction persisting at twelve months in nasolabial folds, and some modern formulations have demonstrated measurable benefit through eighteen months in selected studies.

Perioral treatment tends to involve more movement, while deeper nasolabial or marionette correction may persist differently. The visible result also depends on facial animation, skin quality and whether adjacent volume loss was treated.

For this reason, one universal duration for the entire lower face is not clinically useful.

Filler longevity is influenced by a combination of product chemistry and anatomy. Cross-linking technology, HA concentration, gel elasticity, cohesivity and particle or network characteristics can change how a product behaves in tissue.

Placement also matters. A small amount in a highly mobile superficial area behaves differently from a structural bolus placed deeply over bone. The treated area, baseline anatomy, amount injected and whether previous filler is already present all contribute.

Individual biology matters too, but “metabolism” is often used too casually as an explanation for every difference between patients.

The idea that a “fast metabolism” makes filler disappear quickly is plausible but often stated more confidently than the evidence allows. HA is broken down through local enzymatic and oxidative pathways, but there is no routine clinical test that converts a person’s general metabolic rate into a precise filler-expiry date.

Likewise, frequent exercise is often blamed for shorter filler duration. Exercise changes circulation and energy use, but robust clinical evidence that normal training meaningfully accelerates facial HA degradation is limited.

Smoking and UV exposure are important for skin health and ageing, but they should not be presented as proven switches that rapidly dissolve filler. Good lifestyle advice remains sensible; the specific claim that it reliably extends filler longevity is much weaker.

The safest language is that longevity varies between individuals and cannot be predicted from one lifestyle factor alone.

A filler top-up should be based on reassessment, not an automatic six- or twelve-month subscription.

A review should consider whether the original filler is still present, whether the patient’s anatomy has changed, whether the initial goal remains the same and whether adding more volume would improve or distort the result.

In some patients, the most appropriate plan is to wait. In others, a small adjustment may be reasonable. If there is uncertainty about old filler, asymmetry, nodules or persistent swelling, ultrasound can sometimes help identify product and guide management.

Regular appointments can be useful for review, but they should not automatically mean regular injections.

Hydration is frequently recommended after filler because it is sensible for general health and comfort. It should not be sold as a way to make HA filler last for extra months.

Hyaluronic acid binds water, but drinking more water does not selectively travel into a filler deposit or prevent enzymatic degradation. The same applies to supplements marketed as “filler boosters” unless product-specific clinical evidence exists.

Daily SPF is important for skin health and photoageing prevention. It can help protect the skin surrounding a treated area, but there is not strong clinical evidence that sunscreen directly extends the lifespan of an injected HA gel.

Aftercare should therefore focus on safe recovery and skin health rather than promising that a lifestyle trick will materially prolong filler.

Longer persistence is not always a benefit. Residual filler can coexist with oedema, contour irregularity, nodules, migration or simply a result that no longer matches the patient’s current anatomy.

This is particularly important in areas such as the tear trough and mid-face, where imaging studies show that HA may remain much longer than patients were historically told.

Adding more filler without reassessment can create cumulative volume. If the treated area looks puffy, distorted or persistently swollen, the question should be “What is present now?” rather than “How many months has it been?”

Any filler procedure also carries medical risks. Common reactions include swelling, tenderness and bruising; less common complications include infection, nodules and vascular occlusion. Severe pain, blanching, mottled skin or visual symptoms require urgent assessment.

The most accurate answer to “How long do fillers last?” is not one number. Lips, cheeks, tear troughs, temples, the nose, chin and jawline all behave differently, and the same filler can behave differently in two patients.

Aesthetic effect can fade before the product has completely disappeared. Imaging has made that increasingly clear, particularly in the mid-face. That is why maintenance should be based on the present anatomy rather than on a standard refill interval.

A good filler plan is therefore less about making a product last as long as possible and more about using the right amount, in the right place, for a defined goal — then reassessing before anything else is added.

Related treatment: Dermal fillers